|AHFS/Drugs.com||International Drug Names|
|Elimination half-life||5 hours|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||379.49 g/mol g·mol−1|
|3D model (JSmol)|
Celiprolol is a medication in the class of beta blockers, used in the treatment of high blood pressure. It has a unique pharmacology: it is a selective β1 receptor antagonist, but a β2 receptor partial agonist. It is also a weak α2 receptor antagonist.
Celiprolol is believed to provide clinical benefit for people with vascular Ehlers–Danlos syndrome by promoting normal collagen synthesis in the blood vessels, and by shifting the pressure load away from the vessels most prone to dissection and rupture. Acer Therapeutics is currently developing celiprolol as a potential treatment option specifically for people with vEDS. In 2015, the U.S. Food and Drug Administration (FDA) granted celiprolol orphan drug designation for the treatment of vascular Ehlers–Danlos syndrome.
It was patented in 1973 and approved for medical use in 1982.
Brand names include Cardem, Selectol, Celipres, Celipro, Celol, Cordiax, Dilanorm
- Beridze N, Frishman WH (2012). "Vascular Ehlers-Danlos syndrome: pathophysiology, diagnosis, and prevention and treatment of its complications". Cardiol Rev. 1: 4–7. doi:10.1097/CRD.0b013e3182342316. PMID 22143279.
- Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 461. ISBN 9783527607495.
- Selectol Summary of Product Characteristics (from the IPHA Medicines Compendium)
- Celiprolol data sheet for New Zealand
|This antihypertensive-related article is a stub. You can help Wikipedia by expanding it.|